TAMARANG, S.A. statement:

TAMARANG, S.A. is a pharmaceutical laboratory which is dedicated to developing and supplying medicines with the purpose of improving the quality of life of patients and saving human lives. The medicines should be used with a medical prescription only and exclusively for the therapeutic indications which have been authorised by the health authorities.

The use of the family of medicines known as neuromuscular blocking agents, which includes Rocuronium Bromide, is indicated as an adjunct in general anaesthesia and hospital intensive care. These medicines are used every day in all the hospitals around the world for this therapeutic indication and are commercialised by different pharmaceutical laboratories.

TAMARANG firmly opposes that our medicines could be used for a different purpose to that authorised by the health authorities, and thus we are against the use of our medicine Rocuronium Bromide in cases of capital punishment as a component of lethal injections.

From May 2014, TAMARANG has collaborated actively with the NGO Reprieve, understanding its concerns and communicating with its Director, Maya Foa.

From August 2014, our distributor in the USA, X-GEN, has implemented controls in the distribution of the medicine to prevent its supply to penitentiary hospitals in the United States and its use as a component in the lethal injection in cases of capital punishment.

We reaffirm Tamarang’s commitment and priority that our medicines continue to be used for patients, some of them critically ill, exclusively for the use authorised by the health authorities.

Barcelona, 16th March 2018